To include your compound in the COVID-19 Resource Center, submit it here.

Desirudin cardiovascular data

In a post-hoc analysis of 1,565 evaluable patients in a double-blind, active-controlled, international Phase III trial showed that 15

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE